An interventional study of ACT for Caregivers in Dementia Caregivers, sponsored by Utah State University. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-28.
Sponsored by Utah State University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,049 studies in Dementia with a site in United States — 211 open to participants now, 277 under way, 15 of them phase 3. Dementia · United States.
Among the 1,049 studies in Dementia with a site in United States, this one is the 358th largest by planned enrollment of the 845 interventional ones that give a count, is one of 65 that started in 2026, is one of 561 with no phase, reaches primary completion later than 184 of the 276 other live ones, and was the 1,040th registered.
2,374 studies on the registry are indexed under Dementia; 573 are open to participants now.
Browse Dementia studies →211 of the 1,049 studies in Dementia with a site in United States are open now. Recruiting first, the newest first:
University of Nebraska · Sites in United States
Ages 50+ · Women only · Healthy volunteers
University of Pittsburgh · Sites in United States
Ages 65+
The University of Texas Medical Branch, Galveston · Sites in United States
Ages 50–100 · Healthy volunteers
Weill Medical College of Cornell University · Sites in United States
Ages 21+ · Healthy volunteers
The Cleveland Clinic · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 383 Dementia studies recruiting now, 244 (64%) set no upper age limit and 25 (7%) stop at 75 or younger; 16 take children under 18; 164 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,049 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 73 · Phase 2 146 · Phase 3 79 · Phase 4 33
First in 1981; this study’s year is marked. 65 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is above the median of 90 across 1,760 interventional studies indexed under Dementia.
Median enrollment 93 across the 845 interventional studies, 200 across the 199 observational. Of the 713 that completed or were terminated, 309 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
191 of 1,049 have an industry lead sponsor. The 10 most frequent:
Utah State University is the lead sponsor of 39 studies on the registry; 5 are open to participants now.
Utah State University has 1 study filed under Dementia — fewer than ten, so there is no comparison to draw.
108 of the studies in Dementia with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05543681IGC Pharma, LLCClinical Trial on Agitation in Alzheimer's Dementia | 2026-11 |
| NCT07430371Rendever, Inc.Virtual Reality for Caregiver Assembly, Relief, Empowerment, and Support (VR-CARES) | 2026-11 |
| NCT06095284Virginia Commonwealth UniversityPrescribing Trends and Associated Outcomes of Antiepileptic Drugs in US Nursing Homes Surrounding the COVID-19 Pandemic | 2026-11-30 |
| NCT06298474Hopeful AgingThe BRAIN App (Phase 2 SBIR) | 2026-11-30 |
| NCT07859865Drexel UniversityMindfulness-based Movement Therapy for Persons With Dementia and Family Caregivers | 2026-11-30 |
Add all 108 to your calendar (.ics) → With an account.
Among the 1,049 studies in Dementia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Over 55 million people worldwide have dementia, and in the United States, 80% of people with dementia are cared for at home by family. While family caregivers report positive aspects of their role, many report depressive and anxiety symptoms, and global distress. There is vast heterogeneity in caregivers' experiences, dependent on biopsychosocial risk/contextual factors, and secondary challenges (financial concerns, work disturbances, etc.). While an array of empirically validated interventions can support dementia caregivers, interventions utilizing a transdiagnostic approach can yield improvements in comorbid symptomatology by addressing common underlying mechanisms of chronic or acute conditions, and mechanisms that promote living well with stress.
Acceptance and Commitment Therapy (ACT) is a modern ("third wave") Cognitive Behavioral Therapy (CBT) that addresses clinically significant, or subclinical levels of anxiety, depression, and a myriad of other conditions. The transdiagnostic mechanism in ACT involves increasing psychological flexibility, by changing the impact of negative thoughts and feelings, without having to change the frequency or form of their occurrence. ACT teaches individuals how to engage with painful/stressful experiences and respond with behaviors aligned with their personal values. Across 20 meta-analyses (n=12,477) of ACT clinical trials, ACT is efficacious in improving depression, anxiety, distress, and more. In dementia caregivers, therapist-guided ACT has also yielded improvements in various aspects of psychological distress.
Despite the evidence for ACT improving dementia caregivers' mental health, therapist-delivered interventions are more costly, less convenient, and less "scalable" (i.e. reaching fewer individuals). Online self-guided therapies can be equally effective as face-to-face therapy and are effective for caregivers. In non-caregivers, ACT has been adapted to online, self-guided delivery, demonstrating effective therapeutic results. The investigators' preliminary (Stage I and II) studies provide evidence that ACT is feasible and acceptable in an online, self-guided program tailored to dementia caregivers, and have identified preliminary efficacy in improving the proposed mechanism of change, psychological flexibility, and outcomes of caregiver depression. There is, however, a substantial need to understand if/how psychological flexibility and engagement with ACT for Caregivers work mechanistically to reduce psychological distress for users (with distress defined by the DASS-21 as symptoms of depression, anxiety, and stress). This proposal is responding to the EMBRACE call for mechanism-focused dementia care and caregiver support intervention development, targeting the level of the caregiver. Guided by the Checklist for Investigating Mechanisms in Behavior-change Research (CLIMBR), this Stage II (N=120) waitlist randomized control trial (RCT) will:
With this Stage II study, the investigators examine if the proposed mechanism of change in ACT for Caregivers -- psychological flexibility -- influences changes in caregivers' distress. The investigators also explore how user adherence to the program is associated with changes in both the mediator and the outcome. Gathering evidence on the mechanism of change and intervention adherence is a necessary step in establishing ACT for Caregivers as an empirically validated intervention for dementia caregivers.
Design of the current study:
The proposed study has several design aspects that should be identified and justified. It is a waitlist randomized controlled trial, allowing us a rigorous experimental design for between-person comparisons and robust assessments of mediation between treatment (Tx) and waitlist control (W), while also allowing all participants to get the treatment, and facilitating a larger sample size for within person analyses. See Figure 3 for the timing and delivery of the study assessments.
Participants Power analysis: Using RStudio, the investigators stimulated models using the lme4 package and mediation package. Based on pilot data, the investigators assumed a medium effect across all variables (i.e., X --> M, X--> Y, and M --> Y) and a strong intraclass correlation (ICC = .6). The investigators ran 1000 simulations and found that using a sample size of 120 participants (60 Tx, 60 in waitlist), the investigators were able to identify significant average causal mediation effect, significant average direct effect, a significant total effect, and that the proportion mediated was significant (all ps \< .05). The estimated proportion mediated was approximately 25% (95% CI: [10%,57%]), suggesting the ability to identify meaningful indirect pathways from X to Y via M. These results indicate that a sample size of 120 participants provides adequate power for the mediation analyses. Given that the mediation model represents the most complex analysis in the study and accounts for individual pathways, this sample size will be sufficient to power the direct between- and within-person analyses outlined in both Aim 1 and Aim 2. Based on the pilot study where a 27.7% attrition rate was observed between the first and second timepoints, the investigators will aim to recruit 153 individuals into the study to arrive at the desired sample size of 120.
Recruitment: Family caregivers will be recruited through IRB-approved materials. The investigators will utilize the recruitment methods deemed most effective in the prior Stage I and II studies. Of note, the prior Stage II study recruited 90+ participants across nine months in 2023. The investigators will advertise via 1) the Alzheimer's Association's TrialMatch program, 2) social media and print/online stories distributed by Utah State University, 3) health fairs and events such as the Walk to End Alzheimer's, and 4) existing listservs of community partners. These partners include Utah's Alzheimer's Disease and Related Dementia Coordinating Council (Utah Department of Health and Human Services), and USU's Institute for Disability Research, Policy, and Practice. New approaches for the current study will include accessing the research registry of USU's Alzheimer's Disease and Dementia Research Center, and using the newly-established USU Dementia Caregiver Clinic, which brings in an estimated 80 caregivers per year. The investigators also will utilize the Participant Manager's time to actively recruit out of state to increase geographic and ethnic/racial heterogeneity. The investigators will request that the study opportunity be distributed via the 15 newsletters representing NIA supported ADRC's. With IRB approval, the investigators can request to access the Participant Resource Pool Michigan Center for Urban African American Aging Research (MCUAAAR).
Retention: Participants will receive weekly reminder emails to complete a session, on a day of their choosing. If a participant has lapsed in engagement for two weeks, they will receive a reminder phone call. If attrition occurs, the data from any of the assessments or responses in treatment sessions attended are still useful; as described in the analysis section, an intent to treat analytic approach will be used.
ACT for Caregivers Intervention: The ACT for Caregivers online, self-guided intervention is intended to improve psychological flexibility (via learning to be more open, aware, and engaged), and to improve psychological distress. Participants access 6 sessions (each corresponding to one or more tenets of psychological flexibility), which they work through in order, asynchronously at their own pace, at home. Participants are encouraged (but not mandated) to complete one session per a week over six weeks, with sessions taking 20-40 minutes to complete.
Analyses:
An 'intent to treat' approach will be employed for all participants in the study. Analyses will be completed using Stata 18 (data cleaning) and R 4.0.0 or higher (lme4, nlme). A linear mixed-model will be used, where measurement occasions (Level 1) are nested within individuals (Level 2); treatment condition will be a Level 2 predictor that tests differences between the treatment and waitlist groups from T1 to T3. As observations (Level 1) are nested within individuals' (Level 2) over time, the investigators will employ mediation analyses within a mixed modeling framework. As an RCT examining psychological flexibility (putative mediator = M) as a mechanism underlying the effects of the ACT intervention (intervention = X) on reductions in caregiver psychological distress (outcome = Y), the investigators will conduct the following analyses, consistent with the Checklist for Investigating Mechanisms in Behavior-change Research (CLIMBR).
To assess aim 1, Model 1 will be used to investigate whether participants assigned to treatment with the ACT intervention exhibit decreased psychological distress relative to wait-list control participants, establishing the CLIMBR X --> Y path. To assess aim 2, Model 2 will extend Model 1 to include psychological flexibility as a mediator (M), to evaluate the CLIMBR X --> M and X --> M --> Y linkages articulating the extent to which ACT intervention-related changes in distress are mediated by (increased) psychological flexibility.
Mediation with be formally evaluated by percent reduction in the X --> Y association, tests of indirect effects, and computation of mediator effect sizes in RCTs. Supplemental analyses will consider the subcomponents of psychological flexibility, open, aware, and engaged, to explore the specific dimension(s) driving ACT-related change in psychological distress. Further, chi-square tests of nested model comparisons, evaluating model fit when constraining the magnitude of psychological flexibility effects to be equal, will be employed to determine differences in the magnitude of psychological flexibility components as mediating mechanisms. The investigators will also consider false discovery rates to evaluate potential spurious associations.
To assess aim 3, the investigators will investigate the role of program adherence in associations between psychological flexibility and caregiver psychological distress. The investigators will regress changes in T1 --> T2 and T1 --> T3 psychological flexibility on the number of sessions completed at T2, the operant index of adherence (# sessions completed 75 percent or more), to determine any modulation of effect by adherence. All item-level missingness will be treated using full information maximum likelihood (FIML).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion:
The treatment group will immediately receive access to the intervention following completion of the baseline survey.
Behavioral: ACT for Caregivers
This group will not receive the intervention until 12 weeks post baseline
Behavioral: ACT for Caregivers
ACT for Caregivers is a self-guided digital mental health intervention intended to improve psychological flexibility (via learning to be more open, aware, and engaged), and to improve psychological distress. Participants access 6 sessions (each corresponding to one or more tenets of psychological flexibility), which they work through in order, asynchronously at their own pace, at home. Participants are encouraged (but not mandated) to complete one session per a week over six weeks, with sessions taking 20-40 minutes to complete.
Depression, Anxiety, and Stress Scale (DASS-21)
Depression, Anxiety, and Stress Scale (DASS-21) will be used to assess caregiver's overall psychological distress
Time frame: The DASS-21 will be assessed at baseline, 6-week posttest, and 12-week follow-up.
Zarit Burden Interview-6 (ZBI-6)
The Zarit Burden Interview-6 (ZBI-6) is a 6-item scale designed to assess perceived caregiver burden and strain associated with providing care. Items assess the impact of caregiving on areas such as personal time, relationships, health, and emotional well-being. Responses range from 0 (never) to 4 (nearly always), with higher scores indicating greater caregiver burden
Time frame: The ZBI-6 will be completed at baseline, 6-week posttest, and 12-week follow-up.
Positive Aspects of Caregiving Scale-6 (PACS-6)
The Positive Aspects of Caregiving Scale-6 (PACS-6) is a 6-item scale designed to assess positive perceptions and benefits associated with the caregiving experience, such as feeling useful, appreciated, needed, and more confident. Responses range from 1 (disagree a lot) to 5 (agree a lot), with higher scores indicating greater perceived positive aspects of caregiving.
Time frame: The PACS-6 will be completed at baseline, 6-week posttest, and 12-week follow-up.
Comprehensive assessment of Acceptance and Commitment Therapy processes (CompACT)
The Comprehensive assessment of Acceptance and Commitment Therapy processes (CompACT) is a 23-item scale to assess caregiver psychological flexibility, consisting of three subscales: openness to experience (10 items), behavioral awareness (5 items), and engagement in valued actions (8 items). Responses range from 0 (strongly disagree) to 6 (strongly agree).
Time frame: The CompACT will be completed at baseline, 6-week posttest, and 12-week follow-up.
Adherence Data
Adherence to the program: At the end of each session users are given a message that the session is complete and they "click to end session". This allows them to return to the next session the next time they visit the program and it alerts the researchers that a session is complete. Adherence will be assessed by counting the number of modules that the users completed. If a user has completed 75% of the content and has not clicked to end the session, it will be considered as a completed module.
Time frame: Adherence will be measured 6 weeks post baseline.
Plan to share: No — No identifying data will be shared outside of the IRB approved study team.
Started Jul 2026 (actual). Primary completion is estimated for Dec 2027, 17 months after the start.
Of 861 non-industry interventional studies with no phase under Dementia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 17 months is below that.
Counting every sponsor, half of 907 studies reached it within 25 months; a quarter within 11 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Utah State University